Navigation Links
Oxford University Press enters publishing partnership with Infectious Diseases Society of America
Date:1/25/2010

Oxford Journals, a division of Oxford University Press, and the Infectious Diseases Society of America (IDSA), a leading professional society, have announced a new publishing partnership for IDSA's highly cited and internationally prestigious journals: Clinical Infectious Diseases (CID) and The Journal of Infectious Diseases (JID). Oxford Journals will assume publication of both journals from 1st of January, 2011.

IDSA's twice monthly publications are an excellent fit with Oxford Journals' strong medicine collection, which includes complementary titles in the field of infectious diseases, as well as with OUP's clinical book publishing program.

"Oxford University Press's academic orientation and its emphasis on scientific rigor complement the mission of IDSA," said Richard J. Whitley, MD, FIDSA, president of IDSA. "Our two organizations are committed to the dissemination of scientific knowledge."

Clinical Infectious Diseases, one of the most heavily cited journals in the field, publishes articles on infectious diseases, microbiology, hospital infections, public health, and HIV/AIDS. In 2009 this journal was named one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. CID is edited by Sherwood L. Gorbach, MD, FIDSA.

Founded in 1904, the Journal of Infectious Diseases predates the Society's formation in 1963 and is the premier publication for original research on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune mechanisms. JID is edited by Martin S. Hirsch, MD, FIDSA.

Nigel Portwood, Chief Executive of Oxford University Press, commented: "The IDSA journals are highly prestigious and internationally renowned so the IDSA quite rightly require their publishing partner to deliver the best services available in the industry. The fact that OUP has been chosen to fulfil that requirement is something I and my colleagues are very excited and proud about."


'/>"/>

Contact: Catarina Walsh
Catarina.walsh@oup.com
44-018-653-54206
Oxford University Press
Source:Eurekalert

Related biology news :

1. UMMS and CIW grant key RNAi rights to Oxford Biomedica
2. U. Mass Medical School and Carnegie announce licensing agreements with Oxford BioMedica
3. Oxford Journals and the International Society for Computational Biology announce new partnership
4. Oxfords Dr. Rosalind Rickaby receives 2009 Rosenstiel Award
5. Oxford University Press launches new librarian newsletter
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
9. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
10. Binghamton University researchers investigate evolving malaria resistance
11. Antioxidant to retard wrinkles discovered by Hebrew University researcher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... and sale of advanced technology solutions and products to ... announced the addition of new cohorts of PDX models ... models will expand Champions, product line in hepatocellular cancer, ... cancer, AML, and non-small cell lung cancer (including EGFR ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
Breaking Biology Technology: